堃博醫療-B：年報2023

Futu NewsApr 26 16:34 · Announcements

Broncus Chairman Resigns; Successor Named

Broncus Holding (HKG:2216) said Michael Yi Wei Zhao resigned as chairman of the board and will be succeeded by Hong Xu, according to a Friday filing on the Hong Kong bourse. The changes are effective

MT NewswiresApr 22 11:03

Kunbo Medical-B (02216) appoints Xu Hong as chairman

Kunbo Medical-B (02216) announced that since April 19, 2024, Zhao Yiwei has resigned as a non-executive director,...

Zhitong FinanceApr 19 22:55

Kunbo Medical-B (2216.HK): Rapid growth in endogenous income, looking forward to continued improvement

The company's endogenous revenue grew rapidly in '23, and we expect continuous improvement in '24. The company achieved revenue/net loss of $1026/28.09 million (yoy +8.9%/+0.2%) in '23, which is lower than our expectations (estimated revenue)

華泰證券Mar 31 00:00

Kunbo Healthcare (02216.HK) Announces 2023 Annual Results

The development of lung disease treatment products continues to lead, and product sales are steadily advancing in Hangzhou, March 28, 2024/PRNewswire/ -- On March 28, 2024, Kunbo Medical (02216.HK), a leader in precise interventional diagnosis and treatment of lung diseases in China, announced its annual results for the year ended December 31, 2023. During the reporting period, the company achieved product sales revenue of US$12.41 million, an increase of 32% over the previous year. Among them, the total sales revenue of products in mainland China was US$8.62 million, up 48% year on year. In 2023, the company will have a firm industrial layout around “navigation-diagnosis-treatment”, and it will expand

PR NewswireMar 28 22:27

BRONCUS-B: (I) ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023; AND (II) PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION

Futu NewsMar 28 21:01 · Announcements